135 related articles for article (PubMed ID: 25034990)
1. Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Taneja SS
J Urol; 2014 Aug; 192(2):421-2. PubMed ID: 25034990
[No Abstract] [Full Text] [Related]
2. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
[TBL] [Abstract][Full Text] [Related]
3. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
4. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ; Michaelson MD
Oncologist; 2012; 17(2):288-90. PubMed ID: 22267850
[TBL] [Abstract][Full Text] [Related]
5. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
6. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
8. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
9. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
10. Role of denosumab in prostate cancer.
Helo S; Manger JP; Krupski TL
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):231-6. PubMed ID: 22370723
[TBL] [Abstract][Full Text] [Related]
11. Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer.
Clarke NW
Eur Urol; 2014 Feb; 65(2):287-8. PubMed ID: 23948437
[No Abstract] [Full Text] [Related]
12. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
Galsky MD; Small AC; Tsao CK; Oh WK
CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
[TBL] [Abstract][Full Text] [Related]
13. [The non-hormonal treatment of metastatic prostate cancer].
Mongiat-Artus P; Brenot-Rossi I; Beuzeboc P; Bruyère F; Karsenty G; Guy L; Bastide C
Prog Urol; 2013 Nov; 23(15):1258-64. PubMed ID: 24183084
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer.
Madan RA; Dahut WL
Nat Rev Urol; 2015 Jul; 12(7):368-9. PubMed ID: 26077994
[No Abstract] [Full Text] [Related]
17. Use of denosumab in castration sensitive prostate cancer.
Laurent MR
BMJ; 2023 Dec; 383():2827. PubMed ID: 38049158
[No Abstract] [Full Text] [Related]
18. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
19. Updates in the treatment of bone cancer.
Biermann JS
J Natl Compr Canc Netw; 2013 May; 11(5 Suppl):681-3. PubMed ID: 23704242
[TBL] [Abstract][Full Text] [Related]
20. Do we really need new trials on fulvestrant in prostate cancer?
Féchon A; Droz JP
Onkologie; 2010; 33(1-2):12-3. PubMed ID: 20164656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
